Ultimovacs ASA (ULTI) - Total Liabilities
Based on the latest financial reports, Ultimovacs ASA (ULTI) has total liabilities worth Nkr33.19 Million NOK (≈ $3.49 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ULTI financial resilience to evaluate the company's liquid asset resilience ratio.
Ultimovacs ASA - Total Liabilities Trend (2016–2024)
This chart illustrates how Ultimovacs ASA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ULTI total asset value.
Ultimovacs ASA Competitors by Total Liabilities
The table below lists competitors of Ultimovacs ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Drb Industrial
KO:163560
|
Korea | ₩116.34 Billion |
|
Svolder AB (publ)
ST:SVOL-A
|
Sweden | Skr53.20 Million |
|
Shin Shin Co Ltd
TW:2901
|
Taiwan | NT$196.05 Million |
|
Dish TV India Limited
NSE:DISHTV
|
India | Rs57.40 Billion |
|
Generic Sweden publ AB
ST:GENI
|
Sweden | Skr38.55 Million |
|
OFS Capital Corp
NASDAQ:OFS
|
USA | $191.85 Million |
|
Broendbyernes IF Fodbold AS
CO:BIF
|
Denmark | Dkr244.49 Million |
|
Nila Spaces Limited
NSE:NILASPACES
|
India | Rs1.94 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Ultimovacs ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Ultimovacs ASA balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ultimovacs ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ultimovacs ASA (2016–2024)
The table below shows the annual total liabilities of Ultimovacs ASA from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr33.19 Million ≈ $3.49 Million |
-52.34% |
| 2023-12-31 | Nkr69.65 Million ≈ $7.33 Million |
+15.46% |
| 2022-12-31 | Nkr60.32 Million ≈ $6.35 Million |
-3.31% |
| 2021-12-31 | Nkr62.38 Million ≈ $6.56 Million |
+50.92% |
| 2020-12-31 | Nkr41.34 Million ≈ $4.35 Million |
+23.73% |
| 2019-12-31 | Nkr33.41 Million ≈ $3.52 Million |
+11.53% |
| 2018-12-31 | Nkr29.96 Million ≈ $3.15 Million |
+142.66% |
| 2017-12-31 | Nkr12.35 Million ≈ $1.30 Million |
+81.36% |
| 2016-12-31 | Nkr6.81 Million ≈ $716.29K |
-- |
About Ultimovacs ASA
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.